Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Biogen Inc's Business Segments
Biogen Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of Q2 FY2025
Reportable Segments
1
Largest Segment
Reportable
Total Revenue
$ 2,646
Regions Reported
-
Revenue Share by Reportable Segment - Q2 FY2025
- Reportable100%
Revenue by Reportable Segment - Q2 FY2025
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Reportable | $ 2,646 | 100% |
Revenue by Product & Service Category - Q2 FY2025
- Product71%
- MS Product Revenues24.8%
- Revenues from anti-cd20 therapeutic programs17.7%
- Royalty Attributed To OCREVUS13.4%
- Tysabri product10.3%
- Product and Service, Other9.2%
- Fumarate8.9%
- Rare Disease Product Revenue8.9%
- Contract manufacturing and other revenue8.5%
- VUMERITY7.1%
- Interferon5.7%
- SPINRAZA5.6%
- AVONEX4.6%
- BENEPALI4.2%
- SKYCLARYS2.9%
- Leqembi Collaboration2.1%
- Alzheimer's Collaboration2.1%
- TECFIDERA1.8%
- IMRALDI1.8%
- Other Products1.8%
- ZURZUVAE1.8%
- PLEGRIDY1.1%
- Royalty0.7%
- FLIXABI0.5%
- QALSODY0.3%
- Biosimilars0.1%
- BYOOVIZ0.1%
- FUMADERM And ADUHELM0%
Revenue by Product & Service Category - Q2 FY2025
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Product | $ 1,879 | 71% |
| MS Product Revenues | $ 657 | 24.8% |
| Revenues from anti-cd20 therapeutic programs | $ 467 | 17.7% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
25 more categories available
Sign in to unlock the full Biogen Inc dataset.
Description of Biogen Inc
Business Description of Biogen Inc.
Biogen Inc. is a leading biotechnology company dedicated to advancing the understanding and treatment of neurological and neurodegenerative diseases. Founded in 1978, Biogen has established itself as a pioneer in the field of human healthcare by leveraging scientific research and biopharmaceutical innovation to develop breakthrough therapies. The companys mission is to create transformative therapies for patients with serious neurological conditions and other serious diseases.
Therapeutic Focus Areas
Biogens primary focus areas include:
1. Multiple Sclerosis (MS): Biogen is a key player in the treatment of MS, with a robust portfolio of therapies, including AVONEX (interferon beta-1a), TYSABRI (natalizumab), and OCREVUS (ocrelizumab). These drugs are designed to modify the course of MS and reduce relapses by targeting different mechanisms of action, improving the quality of life for individuals living with this chronic condition.
2. Neurodegenerative Diseases: Biogen has a strong commitment to addressing neurodegenerative diseases such as Alzheimer’s disease and amyotrophic lateral sclerosis (ALS). The company has invested significantly in research and development (R&D) to explore innovative therapies aimed at slowing disease progression and alleviating symptoms.
3. Rare Diseases: Biogen is also focused on rare genetic disorders, including spinal muscular atrophy (SMA). Its innovative treatment, SPINRAZA (nusinersen), has been a game changer for SMA patients, significantly improving motor function and quality of life.
4. Pain and Movement Disorders: The company has explored various treatment options for pain management and movement disorders, aiming to provide solutions for patients suffering from chronic conditions.
Commercial Products
Biogen’s portfolio includes several marketed products beyond those for MS and neurodegenerative diseases. These include therapies for other neurological conditions and rare diseases, successfully addressing unmet patient needs in various therapeutic areas.
Sales and Marketing Strategy
Biogen employs a targeted sales and marketing approach, primarily focusing on specialist physicians who treat the specific diseases its products address. The company utilizes a mix of traditional and modern marketing tactics, including:
- Direct engagement through sales representatives who visit healthcare professionals.
- Participation in professional symposia and conferences to educate physicians on the latest advancements and educate them about their treatments.
- Digital marketing initiatives aimed at providing disease and product-specific information online.
- Establishment of patient support programs that offer guidance, insurance verification, and assistance for accessing medications.
Biogen also maintains patient assistance programs to ensure that eligible patients without insurance can access their necessary therapies at no cost.
Competitive Landscape
The biotechnology and pharmaceutical industries are characterized by rapid innovation and intense competition. Biogen faces competition from a diverse array of companies, ranging from specialized biotech firms to large pharmaceutical corporations. This competition is driven by continuous advancements in science and technology, leading to the development of new and improved treatment options for patients.
In the MS market, Biogen competes with several leading brands. AVONEX competes with drugs such as BETASERON and REBIF, among others. For neurodegenerative diseases, the competition is increasing as new therapies enter the market, making it essential for Biogen to continue its investment in R&D to maintain a competitive edge.
Innovation and Future Outlook
Biogen is deeply committed to innovation and improving patient outcomes through research and development. The companys significant investments in R&D reflect its goal to continue discovering and bringing new therapies to market. As the biotechnology landscape evolves, Biogen aims to remain at the forefront of scientific advancement, ensuring that it meets the needs of healthcare professionals and patients alike in addressing complex neurological and rare diseases.
Biogen Inc. is a leading biotechnology company dedicated to advancing the understanding and treatment of neurological and neurodegenerative diseases. Founded in 1978, Biogen has established itself as a pioneer in the field of human healthcare by leveraging scientific research and biopharmaceutical innovation to develop breakthrough therapies. The companys mission is to create transformative therapies for patients with serious neurological conditions and other serious diseases.
Therapeutic Focus Areas
Biogens primary focus areas include:
1. Multiple Sclerosis (MS): Biogen is a key player in the treatment of MS, with a robust portfolio of therapies, including AVONEX (interferon beta-1a), TYSABRI (natalizumab), and OCREVUS (ocrelizumab). These drugs are designed to modify the course of MS and reduce relapses by targeting different mechanisms of action, improving the quality of life for individuals living with this chronic condition.
2. Neurodegenerative Diseases: Biogen has a strong commitment to addressing neurodegenerative diseases such as Alzheimer’s disease and amyotrophic lateral sclerosis (ALS). The company has invested significantly in research and development (R&D) to explore innovative therapies aimed at slowing disease progression and alleviating symptoms.
3. Rare Diseases: Biogen is also focused on rare genetic disorders, including spinal muscular atrophy (SMA). Its innovative treatment, SPINRAZA (nusinersen), has been a game changer for SMA patients, significantly improving motor function and quality of life.
4. Pain and Movement Disorders: The company has explored various treatment options for pain management and movement disorders, aiming to provide solutions for patients suffering from chronic conditions.
Commercial Products
Biogen’s portfolio includes several marketed products beyond those for MS and neurodegenerative diseases. These include therapies for other neurological conditions and rare diseases, successfully addressing unmet patient needs in various therapeutic areas.
Sales and Marketing Strategy
Biogen employs a targeted sales and marketing approach, primarily focusing on specialist physicians who treat the specific diseases its products address. The company utilizes a mix of traditional and modern marketing tactics, including:
- Direct engagement through sales representatives who visit healthcare professionals.
- Participation in professional symposia and conferences to educate physicians on the latest advancements and educate them about their treatments.
- Digital marketing initiatives aimed at providing disease and product-specific information online.
- Establishment of patient support programs that offer guidance, insurance verification, and assistance for accessing medications.
Biogen also maintains patient assistance programs to ensure that eligible patients without insurance can access their necessary therapies at no cost.
Competitive Landscape
The biotechnology and pharmaceutical industries are characterized by rapid innovation and intense competition. Biogen faces competition from a diverse array of companies, ranging from specialized biotech firms to large pharmaceutical corporations. This competition is driven by continuous advancements in science and technology, leading to the development of new and improved treatment options for patients.
In the MS market, Biogen competes with several leading brands. AVONEX competes with drugs such as BETASERON and REBIF, among others. For neurodegenerative diseases, the competition is increasing as new therapies enter the market, making it essential for Biogen to continue its investment in R&D to maintain a competitive edge.
Innovation and Future Outlook
Biogen is deeply committed to innovation and improving patient outcomes through research and development. The companys significant investments in R&D reflect its goal to continue discovering and bringing new therapies to market. As the biotechnology landscape evolves, Biogen aims to remain at the forefront of scientific advancement, ensuring that it meets the needs of healthcare professionals and patients alike in addressing complex neurological and rare diseases.
Biogen Inc. is a prominent biotechnology company that is at the forefront of developing and commercializing groundbreaking therapies aimed at treating neurological and neurodegenerative diseases. The company maintains a commitment to addressing significant unmet medical needs, particularly in the arena of multiple sclerosis (MS), while also advancing its research endeavors in other related therapeutic areas. Below is a detailed overview of the segments, products, and services Biogen offers.
Product Portfolio
1. Multiple Sclerosis (MS) Treatments
Biogen has established itself as a leader in the development of therapies targeted at various forms of multiple sclerosis, particularly relapsing forms of the disease. The company’s key products in this category include:
- AVONEX:
- AVONEX is a recombinant interferon beta-1a that is administered intramuscularly for the treatment of relapsing forms of multiple sclerosis. This medication has demonstrated efficacy in reducing the frequency of relapses and slowing the progression of disability in MS patients. Since its launch in the U.S. in 1996 and in Europe in 1997, AVONEX has become one of the most widely prescribed MS therapies worldwide. The product is available in both pre-filled syringes and dry powder forms, facilitating ease of use for patients, especially those who may have difficulty with manual dexterity.
- TYSABRI:
- TYSABRI (natalizumab) is a monoclonal antibody that was approved for treating relapsing forms of MS. It functions by inhibiting the migration of immune cells into the central nervous system, thereby reducing inflammation and the formation of lesions. TYSABRI was first launched in 2004 and is also indicated for the treatment of Crohn’s disease. Initially, the product faced market access challenges due to safety concerns surrounding progressive multifocal leukoencephalopathy (PML), a rare but serious brain infection. After extensive safety evaluations, TYSABRI was reintroduced with stringent risk management protocols.
- FAMPYRA:
- FAMPYRA (fampridine) is designed to improve walking ability in adults with MS, addressing a crucial aspect of mobility that many patients struggle with. This drug is the first of its kind focusing specifically on enhancing walking ability in individuals with MS. FAMPYRA has been successfully launched in several European nations and Australia and has shown significant efficacy in helping patients improve their mobility.
Other Therapeutics
Biogen also offers therapies beyond MS, which help address a broader range of neurological and autoimmune diseases:
- RITUXAN:
- Developed in collaboration with Genentech, RITUXAN (rituximab) is a monoclonal antibody utilized for treating conditions like non-Hodgkin lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, and ANCA-associated vasculitis. This drug targets CD20-positive B cells and has a pivotal role in the therapeutic areas of oncology and immunology.
Research and Development
Biogen invests heavily in research and development to expand its therapeutic portfolio. The company dedicates resources to advancing treatment options for various neurological diseases beyond MS, including spinal muscular atrophy (SMA), Alzheimer’s disease, and amyotrophic lateral sclerosis (ALS). Biogen is also active in the development of biosimilars, aiming to increase patient access to biological treatments and ensure affordability.
Services
In addition to its pharmaceutical offerings, Biogen provides a range of services to enhance patient care and treatment adherence:
- Patient Support Programs:
- Biogen has implemented several programs to assist patients through their treatment journeys, from initial diagnosis through to ongoing condition management. These programs include educational resources, counseling, and financial assistance, which are crucial for ensuring access to therapies and helping patients manage their conditions effectively.
- Collaborative Programs:
- Biogen collaborates with healthcare professionals, patient advocacy organizations, and research institutions to facilitate drug development, engage in real-world evidence studies, and support healthcare provider initiatives. This collaborative approach helps improve treatment outcomes and fosters innovation.
- Telehealth Initiatives:
- The company is leveraging telehealth solutions to enhance patient experiences by allowing care to be delivered remotely. This has become increasingly important, especially in light of the COVID-19 pandemic, as it offers patients easier access to healthcare services while minimizing the need for in-person visits.
Future Directions
Biogen remains focused on expanding its treatment portfolio for neurological diseases, with ongoing clinical trials investigating new and novel therapies. The company is dedicated to advancing personalized medicine approaches, utilizing genetic and biomarker information to enable precise treatment targeting based on individual patient profiles.
In essence, Biogen Inc. is a vital player in the biotechnology industry, particularly known for its innovative treatments for multiple sclerosis and its dedication to addressing other serious neurological conditions through continuous research and supportive patient services.
Product Portfolio
1. Multiple Sclerosis (MS) Treatments
Biogen has established itself as a leader in the development of therapies targeted at various forms of multiple sclerosis, particularly relapsing forms of the disease. The company’s key products in this category include:
- AVONEX:
- AVONEX is a recombinant interferon beta-1a that is administered intramuscularly for the treatment of relapsing forms of multiple sclerosis. This medication has demonstrated efficacy in reducing the frequency of relapses and slowing the progression of disability in MS patients. Since its launch in the U.S. in 1996 and in Europe in 1997, AVONEX has become one of the most widely prescribed MS therapies worldwide. The product is available in both pre-filled syringes and dry powder forms, facilitating ease of use for patients, especially those who may have difficulty with manual dexterity.
- TYSABRI:
- TYSABRI (natalizumab) is a monoclonal antibody that was approved for treating relapsing forms of MS. It functions by inhibiting the migration of immune cells into the central nervous system, thereby reducing inflammation and the formation of lesions. TYSABRI was first launched in 2004 and is also indicated for the treatment of Crohn’s disease. Initially, the product faced market access challenges due to safety concerns surrounding progressive multifocal leukoencephalopathy (PML), a rare but serious brain infection. After extensive safety evaluations, TYSABRI was reintroduced with stringent risk management protocols.
- FAMPYRA:
- FAMPYRA (fampridine) is designed to improve walking ability in adults with MS, addressing a crucial aspect of mobility that many patients struggle with. This drug is the first of its kind focusing specifically on enhancing walking ability in individuals with MS. FAMPYRA has been successfully launched in several European nations and Australia and has shown significant efficacy in helping patients improve their mobility.
Other Therapeutics
Biogen also offers therapies beyond MS, which help address a broader range of neurological and autoimmune diseases:
- RITUXAN:
- Developed in collaboration with Genentech, RITUXAN (rituximab) is a monoclonal antibody utilized for treating conditions like non-Hodgkin lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, and ANCA-associated vasculitis. This drug targets CD20-positive B cells and has a pivotal role in the therapeutic areas of oncology and immunology.
Research and Development
Biogen invests heavily in research and development to expand its therapeutic portfolio. The company dedicates resources to advancing treatment options for various neurological diseases beyond MS, including spinal muscular atrophy (SMA), Alzheimer’s disease, and amyotrophic lateral sclerosis (ALS). Biogen is also active in the development of biosimilars, aiming to increase patient access to biological treatments and ensure affordability.
Services
In addition to its pharmaceutical offerings, Biogen provides a range of services to enhance patient care and treatment adherence:
- Patient Support Programs:
- Biogen has implemented several programs to assist patients through their treatment journeys, from initial diagnosis through to ongoing condition management. These programs include educational resources, counseling, and financial assistance, which are crucial for ensuring access to therapies and helping patients manage their conditions effectively.
- Collaborative Programs:
- Biogen collaborates with healthcare professionals, patient advocacy organizations, and research institutions to facilitate drug development, engage in real-world evidence studies, and support healthcare provider initiatives. This collaborative approach helps improve treatment outcomes and fosters innovation.
- Telehealth Initiatives:
- The company is leveraging telehealth solutions to enhance patient experiences by allowing care to be delivered remotely. This has become increasingly important, especially in light of the COVID-19 pandemic, as it offers patients easier access to healthcare services while minimizing the need for in-person visits.
Future Directions
Biogen remains focused on expanding its treatment portfolio for neurological diseases, with ongoing clinical trials investigating new and novel therapies. The company is dedicated to advancing personalized medicine approaches, utilizing genetic and biomarker information to enable precise treatment targeting based on individual patient profiles.
In essence, Biogen Inc. is a vital player in the biotechnology industry, particularly known for its innovative treatments for multiple sclerosis and its dedication to addressing other serious neurological conditions through continuous research and supportive patient services.